Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
21.26
-0.82 (-3.71%)
At close: Apr 24, 2026, 4:00 PM EDT
21.28
+0.02 (0.09%)
After-hours: Apr 24, 2026, 5:13 PM EDT
Aktis Oncology Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a novel radiopharmaceutical platform with lead programs targeting Nectin-4 and B7-H3, both showing promising early clinical and imaging data. Robust supply chain, strong financials, and strategic partnerships position it for broad impact and sustained growth.
-
Radiopharmaceuticals are poised for major growth, with new miniprotein binder technology enabling first-in-class therapies targeting Nectin-4 and B7-H3. Robust supply chain, strategic partnerships, and a strong team support rapid clinical advancement and broad market potential.